Stay updated on Cetuximab and Pembrolizumab in Colorectal Cancer Clinical Trial
Sign up to get notified when there's something new on the Cetuximab and Pembrolizumab in Colorectal Cancer Clinical Trial page.

Latest updates to the Cetuximab and Pembrolizumab in Colorectal Cancer Clinical Trial page
- Check6 days agoChange DetectedAdded a Locations section listing New York and Ohio as study sites; this consolidates the prior New York Locations and Ohio Locations entries. The page revision was updated to v3.3.3 and the HHS Vulnerability Disclosure link was removed from the footer.SummaryDifference0.3%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check35 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2. No visible changes to the study details or page behavior.SummaryDifference0.1%

- Check42 days agoChange DetectedThe funding-status banner regarding government operations has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check63 days agoChange DetectedThe screenshots indicate only minor UI/layout updates with no changes to core study content (title, objectives, eligibility, endpoints, or locations). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check85 days agoChange DetectedUpdate includes a prominent operating-status notice and a version upgrade from v3.1.0 to v3.2.0. The core effect is informing users about possible delays and the current open status of the NIH Clinical Center.SummaryDifference3%

- Check92 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Cetuximab and Pembrolizumab in Colorectal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cetuximab and Pembrolizumab in Colorectal Cancer Clinical Trial page.